Shinichiro Fuse
Managing Director at TPG
Shinichiro Fuse
Managing Director at TPG
Cambridge, Massachusetts
Overview
Work Experience
Partner/Managing Director
2021 - Current
Partner/Co-Lead, Life Sciences Innovations (LSI) Fund. Investments: Santa Ana Bio (Board), Sudo Biosciences (Board).
TPG is a private investment firm that manages capital across a series of funds.
Raised $535,598,425.00 from Macquarie Group, Ares Management, Nomura Holdings, Pierfront Capital, Kohlberg Kravis Roberts, Partners Group and Barings.
Board Member
2020 - 2021
Interim CEO / Board Member
2019 - 2020
Circular RNA newco, MIT spinout (fka Oroboros)
Orna Therapeutics is a biotechnology company that specializes in fully engineered circular RNA therapeutics to treat various diseases.
Raised $321,000,000.00 from MPM Capital, BioImpact and Merck.
Advisor
2019 - 2021
Board observer
Founding/Interim Senior Vice President, Business Development
2017 - 2019
Led BD for ElevateBio (MPM newco) from launch - BD strategy, deal sourcing, diligence, transactions, establishment of Elevate subsidiaries, alliance management. Launched newcos/deals include AlloVir (fka Viracyte), HighPassBio, and other stealth newco's. Supported initial LifeEdit negotiations.
ElevateBio is a biotechnology company that specializes in cell and gene-based therapies.
Raised $1,246,000,000.00 from ITOCHU Corporation, Emerson Collective, EDBI, Vertex Ventures, Fidelity, Samsara BioCapital, Novo Nordisk, Invus, Woodline Partners and Matrix Capital Management.
Managing Director
2018 - 2021
Life science venture capital & newco building. Investments: Orna (board + interim CEO), Triplet Therapeutics (board), ElevateBio (board observer), AlloVir (NASDAQ: ALVR), Repare Therapeutics (RPTX, board observer til IPO), CODA Biotherapeutics (board observer), iTeos Therapeutics (ITOS), 28-7, iOmx Therapeutics (board, starting 06/2020-), Crossbow
Principal
2016 - 2018
MPM BioImpact is a biotechnology investment firm specializing in managing early-stage venture and private/public impact.
Director, Business Development
2015 - 2016
Deal sourcing, diligence, negotiations, alliance management, strategy, and competitive intelligence. Lead/support on academic/corporate licenses/options, sponsored research, and M&A (Pregenen).
Senior Manager, Business Development
2014 - 2015
Bluebird Bio is a biopharma company that develops and commercializes gene therapies for the treatment of severe genetic diseases and cancer.
Raised $3,436,600,000.00 from Hercules Capital.
Engagement Manager
2013 - 2014
Corporate Development team: Business development, corporate strategy, valuation, revenue forecasting, launch planning, indication prioritization.
Senior Consultant
2012 - 2013
Associate
2011 - 2012
Founding & operational team of Vedanta Biosciences (microbiome) and Mandara Sciences (nutrition). Technology sourcing, due diligence, deal support, and newco building.
Consultant
2009 - 2011
Healthcare strategy consulting, primarily in oncology and immunology. Business development, corporate strategy, revenue forecasting, sales operations, launch planning.
Associate Consultant
2008 - 2009
Summer Associate
2007 - 2007
Institutional Equities Division (Equity Research, Equity Sales & Trading). Industry and company analysis.
Morgan Stanley Venture Partners is a private equity firm that invests in high-growth companies in the technology and healthcare industries.